Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy: The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements

Cancer

Volumn 78, Issue 3, 1996, Pages 480-486

  Rabbani, Farhang ^a   Gleave, Martin E ^a   Coppin, Christopher M ^b   Murray, Nevin ^b   Sullivan, Lorne D ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

lymph node dissection; metastases; postchemotherapy; teratoma; testis tumor

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; BLEOMYCIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; ETOPOSIDE; LACTATE DEHYDROGENASE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; HISTOPATHOLOGY; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NON SEMINOMATOUS GERMINOMA; PARAAORTIC LYMPH NODE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TESTIS TERATOMA;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; GERMINOMA; HUMANS; LOGISTIC MODELS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; RETROPERITONEAL SPACE; RETROSPECTIVE STUDIES; TERATOMA; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0029894542     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960801)78:3<480::AID-CNCR15>3.0.CO;2-V     Document Type: Article

References (21)

1. Lange PH, Fraley EE. Controversies in the management of low volume stage II nonseminomatous germ cell testicular cancer. Semin Oncol 1988;15:324-34.
2. Cleave ME, von Eschenbach AC. Testicular tumors. In: Krane RJ, Siroky MB, Fitzpatrick J, editors. Clinical urology. Philadelphia: JB Lippincott, 1994:1143-75.
3. Einhorn LH. Complicated problems in testicular cancer. Semin Urol 1988;15:9-15.
4. Mostofi FK, Sobin LH. Histological typing of testis tumours. International histological classification of tumours, no. 16. Geneva: World Health Organization, 1977.
5. Murray N, Coppin C, Swenerton K. Weekly high intensity cisplatin etoposide (HIPE) for far advanced germ cell cancers (GCC). Proc Am Soc Clin Oncol 1987;6:101.
6. Stomper PC, Jochelson MS, Garnick MB, Richie JP. Residual abdominal masses after chemotherapy for nonseminomatous testicular cancer: correlation of CT and histology. AJR 1985;145:743-6.
7. Wishnow KI, Johnson DE, Swanson DA, Tenney DM, Babaian RJ, Dunphy CH, et al. Identifying patients with lowrisk clinical stage I nonseminomatous testicular tumors who should be treated by surveillance. Urology 1989;34:339-43.
8. Norusis MJ, SPSS Inc. SPSS for Windows: Advanced statistics, Release 6.0. Chicago: SPSS Inc., 1993.
9. Einhorn LH. Combination chemotherapy with cis-dichlorodiammine-platinum in disseminated testicular cancer. Cancer Treat Rep 1979;63:1659-62.
10. Vugrin D, Whitmore WF Jr., Golbey RB. Vinblastine, actinomycin D, bleomycin, cyclophosphamide and cisplatinum combination chemotherapy in metastatic testis cancer - a 1-year program. J Urol 1982;128:1205-8.
11. Rowland RG, Donohue JP. Scrotum and testis. In: Gillenwater JY, Grayhack JT, Howards SS, Duckett JW, editors. Adult and pediatric urology. 2nd ed. St. Louis: Mosby-Year Book, 1991;1565-98.
12. von Eschenbach AC, Cleave ME, Swanson DA. Conservative management of the retroperitoneum for stages I and II nonseminomatous germ cell tumors. World J Urol 1992;10:43-8.
13. Swanson DA. Should chemotherapy replace retroperitoneal lymphadenectomy for clinical stage II testicular tumors? [editorial]. Mayo Clin Proc 1995;70:911-3.
14. Herr HW, Toner GC, Geller NL, Bosl GJ. Patient selection for retroperitoneal lymph node dissection after chemotherapy for nonseminomatous germ cell tumors. Eur Urol 1991;19:1-5.
15. Fossa SD, Aass N, Ous S, Hoie J, Stenwig AE, Lien HH, et al. Histology of tumor residuals following chemotherapy in patients with advanced nonseminomatous testicular cancer. J Urol 1989;142:1239-42.
16. Toner GC, Panicek DM, Heelan RT, Geller NL, Lin S-Y, Bajorin D, et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol 1990;8:1683-94.
17. Carter GE, Lieskovsky G, Skinner DG, Daniels JR. Reassessment of the role of adjunctive surgical therapy in the treatment of advanced germ cell tumors. J Urol 1987;138:1397-401.
18. Sagalowsky AI, Ewalt DH, Molberg K, Peter PC. Predictors of residual mass histology after chemotherapy for advanced testis cancer. Urology 1990;35:537-42.
19. Donohue JP, Rowland RG, Kopecky K, Steidle CP, Geier G, Ney KG, et al. Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. J Urol 1987;137:1176-9.
20. Lerner SE, Mann BS, Blute ML, Richardson RL, Zincke H. Primary chemotherapy for clinical stage II nonseminomatous germ cell testicular tumors: selection criteria and longterm results. Mayo Clin Proc 1995;70:821-8.
21. Swanson DA, von Eschenbach AC, Babaian RJ, Dinney CPN. The advantages of retroperitoneal lymph node dissection instead of initial chemotherapy for clinical stage II nonseminomatous germ cell testicular tumors. J Urol 1995;153:244A.